Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ) has announced that its independently developed innovative drug, BIOS0635-048 tablets, has received a Clinical Trial Approval Notice from the National Medical Products Administration (NMPA). The approval permits the company to conduct clinical trials evaluating the drug as a monotherapy in patients with advanced solid tumors.

BIOS0635-048 is a novel small-molecule inhibitor independently developed by the company, intended for the treatment of various solid tumors. The drug targets specific epigenetic factors closely linked to the development and progression of multiple cancers. It acts at the transcriptional level to inhibit endocrine receptors, potentially overcoming resistance to endocrine therapies. Furthermore, this compound can modulate the cell cycle and MYC levels, offering a new therapeutic option for patients with solid tumors.

Currently, no drug targeting this specific mechanism has been approved for marketing globally. The registration classification for this drug is Chemical Drug Class 1, indicating it is a new molecular entity.